Hematologic Malignancy
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CI-CAN-00000765Explore in graph →
Hematologic298 active trials6 approved drugs47 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000765Explore in graph →
Clinical trials
1,406 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (273)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02371590 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT03417414 | Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases? | unknown | — | 160 | Ottawa Hospital Research InstituteOTHER | 0 | Feb 7, 2018 | clinicaltrials |
| NCT01181258 | Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies | completed | Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01805375 | A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies | completed | Phase 1 | 28 | Cancer Research UKOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | terminated | Phase 2 | 25 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01460134 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | completed | Phase 1 | 90 | Celldex TherapeuticsINDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01400685 | Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Jan 25, 2018 | clinicaltrials |
| NCT02294552 | Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | completed | Phase 2 | 200 | Ivan S MoiseevOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT03398967 | A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT02200848 | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 | 5 | Georgetown UniversityOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01534715 | IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 49 | ImmunoGen, Inc.INDUSTRY | 2 | Dec 29, 2017 | clinicaltrials |
| NCT03383952 | A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia | unknown | Phase 1 | 20 | Immune Cell, Inc.INDUSTRY | 1 | Dec 27, 2017 | clinicaltrials |
| NCT00438854 | Dasatinib in Relapsed Chronic Lymphocytic Leukemia | completed | Phase 2 | 15 | Massachusetts General HospitalOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00764517 | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 57 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 11, 2017 | clinicaltrials |
| NCT00060424 | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia | completed | Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 8, 2017 | clinicaltrials |
| NCT00565981 | A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response | completed | Phase 2 | 10 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Nov 30, 2017 | clinicaltrials |
| NCT01110473 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | completed | Phase 1 | 52 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00466895 | Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. | completed | Phase 1 | 37 | Leslie AndritsosOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02132624 | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. | completed | Phase 1 / Phase 2 | 15 | Uppsala UniversityOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT01239394 | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | completed | Phase 2 | 43 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00476047 | Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission | completed | Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01682044 | Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma | completed | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Oct 9, 2017 | clinicaltrials |
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01369849 | Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01399840 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | completed | Phase 1 | 33 | PfizerINDUSTRY | 2 | Sep 15, 2017 | clinicaltrials |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02013817 | CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy | completed | Phase 2 | 43 | Hoffmann-La RocheINDUSTRY | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00738374 | A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. | completed | Phase 2 | 97 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01500083 | Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia(BENDACT) | completed | Phase 3 | 90 | Lundbeck Canada Inc.INDUSTRY | 1 | Aug 14, 2017 | clinicaltrials |
| NCT00159003 | Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel | completed | — | 100 | Deborah RundOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00090051 | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients | completed | Phase 3 | 552 | Hoffmann-La RocheINDUSTRY | 17 | Aug 1, 2017 | clinicaltrials |
| NCT00281983 | Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 100 | German CLL Study GroupOTHER | 2 | Jul 24, 2017 | clinicaltrials |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | terminated | Phase 2 / Phase 3 | 5 | University of Alabama at BirminghamOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT02981745 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | 200 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00801281 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.(PLRG4) | completed | Phase 3 | 250 | Polish Lymphoma Research GroupNETWORK | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00587457 | A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia | terminated | Phase 1 | 11 | MedImmune LLCINDUSTRY | 2 | Jul 6, 2017 | clinicaltrials |
| NCT00058240 | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00366418 | Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia | completed | Phase 1 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Jul 2, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00614042 | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma | completed | Phase 1 | 96 | Aptevo TherapeuticsINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | N/A | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT02381080 | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | completed | Phase 1 | 26 | Janssen Research & Development, LLCINDUSTRY | 3 | Jun 26, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2018source: clinicaltrials